Jeon HJ, et al. - Whether a combination drug therapy that consists of dapagliflozin with three other oral hypoglycemic agents (OHAs) would have a beneficial safety and efficacy profile in T2DM patients who have uncontrolled glucose levels compared to a treatment regimen that contains of basal insulin with two different OHAs were evaluated in this study. For this analysis, an aggregate of one hundred sixty-two type 2 diabetic patients who are unable to control glucose on their current therapy consisting of 3 OHAs were enrolled in dapagliflozin group and one hundred forty-eight patients in insulin glargine group for the 24-week study period. According to the findings obtained, the addition of dapagliflozin to an existing drug regimen consisting of 3 different OHAs in patients presenting inadequate blood glucose control could be alternate treatment modality in T2D who hesitate to start insulin therapy.